English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/50433
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

DC FieldValueLanguage
dc.contributor.authorCalviño, Eva-
dc.contributor.authorEstañ, María Cristina-
dc.contributor.authorSimón, Gloria P.-
dc.contributor.authorSancho, Pilar-
dc.contributor.authorBoyano-Adánez, María del Carmen-
dc.contributor.authorBlas, Elena de-
dc.contributor.authorBréard, Jacqueline-
dc.contributor.authorAller, Patricio-
dc.date.accessioned2012-05-30T11:33:30Z-
dc.date.available2012-05-30T11:33:30Z-
dc.date.issued2011-12-01-
dc.identifier.citationBiochemical Pharmacology 82(11):1619-1629(2011)es_ES
dc.identifier.issn0006-2952-
dc.identifier.urihttp://hdl.handle.net/10261/50433-
dc.description11 páginas, 7 figuras, 3 figuras suplementarias -- PAGS nros. 1619-1629es_ES
dc.description.abstractLonidamine is a safe, clinically useful anti-tumor drug, but its efficacy is generally low when used in monotherapy. We here demonstrate that lonidamine efficaciously cooperates with the anti-leukemic agent arsenic trioxide (ATO, Trisenox™) to induce apoptosis in HL-60 and other human leukemia cell lines, with low toxicity in non-tumor peripheral blood lymphocytes. Apoptosis induction by lonidamine/ATO involves mitochondrial dysfunction, as indicated by early mitochondrial permeability transition pore opening and late mitochondrial transmembrane potential dissipation, as well as activation of the intrinsic apoptotic pathway, as indicated by Bcl-XL and Mcl-1 down-regulation, Bax translocation to mitochondria, cytochrome c and Omi/HtrA2 release to the cytosol, XIAP down-regulation, and caspase-9 and -3 cleavage/activation, with secondary (Bcl-2-inhibitable) activation of the caspase-8/Bid axis. Lonidamine stimulates reactive oxygen species production, and lonidamine/ATO toxicity is attenuated by antioxidants. Lonidamine/ATO stimulates JNK phosphorylation/activation, and apoptosis is attenuated by the JNK inhibitor SP600125. In addition, lonidamine elicits ERK and Akt/mTOR pathway activation, as indicated by increased ERK, Akt, p70S6K and rpS6 phosphorylation, and these effects are reduced by co-treatment with ATO. Importantly, co-treatment with MEK/ERK inhibitor (U0126) and PI3K/Akt (LY294002) or mTOR (rapamycin) inhibitors, instead of ATO, also potentiates lonidamine-provoked apoptosis. These results indicate that: (i) lonidamine efficacy is restrained by drug-provoked activation of MEK/ERK and Akt/mTOR defensive pathways, which therefore represent potential therapeutic targets. (ii) Co-treatment with ATO efficaciously potentiates lonidamine toxicity via defensive pathway inhibition and JNK activation. And (iii) conversely, the pro-oxidant action of lonidamine potentiates the apoptotic efficacy of ATO as an anti-leukemic agentes_ES
dc.description.sponsorshipThis work was supported by the Ministerio de Ciencia e Innovación, Spain, Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica, Dirección General de Investigación (Grants SAF2007-64721 and SAF-2010-20256) and Programa Consolider-Ingenio 2010 (Grant CSD-00020); and by the Consejo Superior de Investigaciones Científicas (Grant 201020E037). M.C.E. is recipient of a JAE-Predoc fellowship from de Consejo Superior de Investigaciones Científicas. G.P.S. is the recipient of a “Contrato de Personal Investigador de Apoyo”, Dirección General de Universidades e Investigación, Consejería de Educación, Comunidad de Madrid. The authors are very grateful to Dr. M. De las Casas (Centro de Investigaciones Biológicas, Consejo Superior de Investigaciones Científicas) for supply of freshly isolated lymphocyteses_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.rightsclosedAccesses_ES
dc.subjectLonidaminees_ES
dc.subjectLonidaminees_ES
dc.subjectArsenic trioxidees_ES
dc.subjectApoptosises_ES
dc.subjectROSes_ES
dc.subjectProtein kinaseses_ES
dc.titleIncreased apoptotic efficacy of lonidamine plus arsenic trioxide combination in human leukemia cells. Reactive oxygen species generation and defensive protein kinase (MEK/ERK, Akt/mTOR) modulationes_ES
dc.typeartículoes_ES
dc.identifier.doi10.1016/j.bcp.2011.08.017-
dc.description.peerreviewedPeer reviewedes_ES
dc.relation.publisherversionhttp://dx.doi.org/10.1016/j.bcp.2011.08.017es_ES
dc.identifier.e-issn1873-2968-
Appears in Collections:(CIB) Artículos
Files in This Item:
There are no files associated with this item.
Show simple item record
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.